A fully integrated lifecycle model connecting every stage of the journey, from concept to implementation and beyond. A model that brings together clinical leadership and technology through one alliance. One that transforms complexity into clarity. Aligns vision with execution. Helping healthcare providers build, launch, optimize, and grow world-class oncology programs.
Why We Exist
The challenge
Today, organizations looking to establish advanced oncology programs must navigate a fragmented ecosystem of vendors, consultants, and service providers. With critical components managed separately, accountability is often dispersed, making execution more complex and increasing risk.
We exist to provide a more integrated path forward.
Our approach
Successful cancer programs require more than world-class technology. They require a partner with the expertise, experience, and commitment to guide organizations from strategy and planning through implementation, optimization, and long-term growth.
We stand alongside our partners every step of the journey, delivering the accountability, expertise, and support needed to turn vision into reality.
How We Work
We bring together clinical, operational, and technical expertise and work alongside our partners to turn oncology strategy into sustainable results.
Our work is grounded in decades of specialized experience across radiation oncology, proton therapy, healthcare operations, and technology implementation. We apply proven clinical, technical, and business expertise to help organizations make informed decisions, navigate complexity, and achieve lasting success.
We believe successful oncology programs are built through collaboration, not transactions. As a long-term partner, we align clinical, operational, and strategic expertise to help healthcare organizations create sustainable programs that deliver exceptional patient care and lasting value.
Trust is earned through objectivity, transparency, and accountability. We help healthcare organizations make informed decisions and achieve sustainable clinical, operational, and financial outcomes, with success measured by the lasting impact of the programs we support.
Services
Choose a stage to explore the capabilities that support clinical, operational, and financial success.
Develop
Move customers from concept to investment approval.
Market assessment, demand forecasting, strategic options analysis and capacity planning
Capital planning, financing strategy and partnership structure
Financial modeling, ROI analysis, stakeholder alignment and investment committee support
Build
Prepare the organization for successful go-live and first patient treatment.
Program management, goverance, reporting and risk management
Clinical model development, indication strategy and care model design
Facility planning, patient flow design and operational planning
Workflow design, commissioning readiness and go-live preparation
Staffing models and organizational design
Clinical and operational training, competency development and knowledge transfer
Accreditation, compliance, quality systems and safety program
Treat
Drive volume growth, operational maturity and long-term program success.
Referral strategy, physician engagement and outreach programs
Access optimization,scheduling and patient engagement/experience initatives
Throughput improvement, KPI development, capacity optimzation and cost reducation
Benchmarking, peer review, outcomes measurement and quality improvement, quality & safety audit, medical physics excellence, treatment planning support
The Alliance
About Penn Medicine
Penn Medicine serves as Noventra's clinical partner, bringing more than a decade of leadership in proton therapy delivery, research, and program development. As a world-renowned academic medical center and leader in radiation oncology, Penn Medicine operates one of the largest and most experienced proton therapy programs in the world. Since 2010, Penn Medicine has treated more than 11,500 unique patients and delivered over 340,000 proton therapy treatments, establishing a proven track record of clinical excellence, operational performance, and patient-centered care.
Through decades of experience in clinical practice, reimbursement, market access, research, and academic innovation, Penn Medicine contributes deep expertise and proven best practices across the proton therapy continuum. As a recognized leader in education and workforce development, Penn has trained more than 80% of the current proton therapy providers globally, helping advance the adoption of proton therapy and shape the future of cancer care. This combination of clinical expertise, operational experience, and academic leadership enables Noventra to support partners in developing, expanding, and optimizing proton therapy programs that achieve both clinical and organizational success.
About IBA
IBA serves as Noventra's technology partner, bringing more than three decades of leadership in particle therapy innovation and implementation. As the global leader in particle therapy technology, IBA has built the world's largest installed base of proton therapy systems and helped leading cancer centers globally establish and expand their proton therapy program. Through decades of experience in development, implementation, and operational support, IBA contributes deep technical expertise, proven best practices, and access to a global community of world-class proton therapy centers. This international ecosystem provides Noventra and its partners with valuable insight into program development, operational excellence, clinical advancement, and innovation.
Penn Medicine
Chair, Department of Radiation Oncology
Henry K. Pancoast Professor
James M. Metz, MD is the Henry K. Pancoast Professor and Chair of Radiation Oncology in the Perelman School of Medicine at the University of Pennsylvania. Dr. Metz also served as the Executive Director of OncoLink, the world’s largest award-winning Internet resource for cancer information. Read Full Bio
IBA
Chief Executive Officer
Vice Chairman of the Board
After four years as auditor with Didier Claes and Associates, Olivier joined IBA SA in 1996 as Controller and was particularly involved in the IPO of the company. In 1998 he was appointed Chief Financial Officer (CFO) of Scanditronix Medical AB Sweden, the new subsidiary of IBA’s dosimetry activities. Read Full Bio
Leadership
Our team brings together clinical, operational, strategic, and technical expertise to help healthcare organizations navigate complexity and build successful oncology programs.
President
Global leader of Noventra; leverage in-depth industry knowledge to help healthcare providers accelerate the development of world-class oncology programs.
Head of Program
Leads client engagements and advisory services, supporting healthcare organizations in designing, launching and optimizing care programs.
Contact Us
Tell us where you are in the oncology program lifecycle and what you are looking to achieve.
